Flibanserin (Addyi) is now approved for treating HSDD in postmenopausal women, expanding its previous indication for premenopausal women. The FDA's priority review designation for flibanserin ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback